Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis
- 18 July 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 27 (2), 416-422
- https://doi.org/10.1038/leu.2012.205
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Prognostic Impact of Morphologic and Phenotypic Features of Childhood ALK-Positive Anaplastic Large-Cell Lymphoma: Results of the ALCL99 StudyJournal of Clinical Oncology, 2011
- Single-Drug Vinblastine As Salvage Treatment for Refractory or Relapsed Anaplastic Large-Cell Lymphoma: A Report From the French Society of Pediatric OncologyJournal of Clinical Oncology, 2009
- Classification OMS 2008 des lymphomesAnnales de Pathologie, 2008
- Kinetics of humoral response to ALK and its relationship with minimal residual disease in pediatric ALCLLeukemia, 2008
- Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup studyBlood, 2008
- Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK–positive anaplastic large-cell lymphomaBlood, 2007
- The impact of age and gender on biology, clinical features and treatment outcome of non‐Hodgkin lymphoma in childhood and adolescenceBritish Journal of Haematology, 2005
- Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphomaLeukemia, 2005
- Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90Blood, 2001
- Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphomaBlood, 2000